Ovarian cancer patients in Saskatchewan whose tumours resist standard chemotherapy will get provincial coverage for two new drugs, starting December 1. The decision ends years in which the treatments existed — but only for women able to pay for them out of pocket.
Radio-Canada reported the announcement this week: the province will cover Elahere and Keytruda, both given by intravenous infusion, for eligible patients whose disease no longer responds to platinum-based chemotherapy — the backbone of first-line ovarian cancer treatment.
Until now, the drugs were available only in limited circumstances, and the cost fell to patients, provincial Health Minister Jeremy Cockrill explained. Reimbursement could cost Saskatchewan up to $500,000 a year. The provincial government estimates eight to ten women annually will qualify.
The stakes are high because ovarian cancer is frequently diagnosed at an advanced stage — its symptoms are easy to mistake for less serious conditions — and options narrow sharply once platinum chemotherapy stops working.
“The fact that Saskatchewan is the first in Canada to do this is extremely important for us,” said Anne Chase, a founding member of the advocacy group Saskatchewan Ovarian Cancer Survivors, in an interview with Radio-Canada, according to Radio Canada.
Pays for Elahere and Keytruda for Eligible Patients
- From December 1, the province pays for Elahere and Keytruda for eligible patients — the out-of-pocket barrier disappears for those women.
- The drugs are reserved for patients whose disease has stopped responding to platinum-based chemotherapy, the standard first treatment.
- Roughly eight to ten women a year in Saskatchewan are expected to meet the criteria.
What the Two Drugs Actually Do
Elahere is an antibody-drug conjugate — in plain terms, a guided missile. Its mechanism of action links an antibody that homes in on folate receptor alpha, a protein abundant on many ovarian cancer cells, to a chemotherapy payload, delivering the toxic drug inside the tumour while sparing more healthy tissue than conventional chemotherapy.
Keytruda, known generically as pembrolizumab, works on the immune system instead. It is a PD-1 inhibitor: it blocks the molecular “off switch” that tumours use to make immune T-cells stand down, allowing the body’s own defences to re-engage the cancer.
According to the provincial government, clinical studies have shown the treatments can slow disease progression and prolong survival in some patients.
The reimbursement decision sits inside a much larger provincial cancer budget. Denise Budz, vice-president of care services at the Saskatchewan Cancer Agency, considers the expanded therapeutic options a better answer to the needs of eligible patients, Radio-Canada reported.
| Measure | Figure |
|---|---|
| Added annual cost to the province | Up to $500,000 |
| Coverage begins | December 1 |
The agency’s $308.6-million budget for 2026–2027 covers prevention, diagnosis, treatment and research across the province. The new drug coverage — at most half a million dollars — represents a small fraction of that envelope, but a decisive one for the small group of women it reaches.
Diagnosed in 1998, Still Waiting
Chase, now 82, has lived with the disease’s limited arsenal for nearly three decades. She was diagnosed with ovarian cancer in 1998 and has campaigned for years to raise public awareness of the illness and improve access to treatment, Radio-Canada reported.
She deplores how few new therapeutic options women with this cancer have been offered over the decades — a scarcity that made Monday’s kind of announcement, in her view, a long time coming.
Her testimony echoes the difficulty patients face when standard treatments stop working and the list of funded alternatives runs out.
Quebec Balked at Keytruda’s Price
Saskatchewan’s move did not happen in a vacuum. In October, the pan-Canadian Pharmaceutical Alliance concluded agreements in principle with the manufacturers of Elahere and Keytruda, opening the way for individual provinces to make reimbursement decisions.
Not every province is following the same path. In September, Quebec’s INESSS — the institute that assesses the cost-effectiveness of new treatments — recommended against reimbursing Keytruda for ovarian cancer, judging its price too high relative to the clinical benefits observed. The ministerial decision on that recommendation has been postponed.
That divergence is the crux of the story: the science is settled enough for Saskatchewan to pay, yet one provincial reviewer judged the same drug’s benefit insufficient for its cost. Patients in different provinces may face different answers to the same diagnosis.
What Comes After December 1
Saskatchewan goes first, but the October agreements in principle mean every province now has a negotiated price to work from. Whether others follow — and on what terms — is the question the next provincial budgets will answer.
In Quebec, the ministerial decision on reimbursing Keytruda for ovarian cancer remains postponed.
References
- Radio-Canada — “Deux nouveaux traitements contre le cancer des ovaires seront accessibles” (source of the announcement, cost figures, eligibility estimates and interviews)
- Government of Saskatchewan, Ministry of Health — reimbursement announcement
- Saskatchewan Cancer Agency — 2026–2027 budget and care services
- INESSS (Institut national d’excellence en santé et en services sociaux, Quebec) — September recommendation on Keytruda
- Pan-Canadian Pharmaceutical Alliance — October agreements in principle
Disclaimer: This article is journalistic coverage of a health policy announcement and is not medical advice. Treatment decisions for ovarian cancer should be made with a qualified oncologist.